ERS Genomics Appoints John E Milad as Chief Executive Officer
2024年5月13日 - 6:33PM
ビジネスワイヤ(英語)
ERS Genomics Limited (‘ERS’), the CRISPR licensing company,
today announced the appointment of John E Milad as CEO, with
immediate effect. John brings over 25 years of experience as an
executive leader, venture capitalist, and investment banker focused
on the life sciences and medical technology sectors.
As CEO of Quanta Dialysis Technologies for nearly a decade, John
led the development and commercial launch of an award-winning
portable haemodialysis system designed to transform the delivery of
kidney care to patients. He drove market entry into the UK and US,
while raising a record-breaking $245 million private funding round
and building an extensive intellectual property estate of over 40
patent families. Prior to this, he served as CFO of Nitec Pharma,
where he headed up finance and business development activities,
raising a pivotal funding round and securing a licensing partner to
enable the company’s transition from clinical development to
commercialisation.
John also has significant experience as a venture investor, with
previous roles as Partner and co-Head of Healthcare Ventures at
Downing LLP and Investment Director at NBGI Ventures, as well as
positions at Atlas Venture and Kirkland Investors. Successful
exited investments include Symetis, ACT/Epix, BoneSupport and
WebMD.
A graduate of the University of Chicago, John served on the i4i
selection panel for translational research at the National
Institute for Health and Care Research (NIHR). John currently
serves on the Boards of Kidney Research UK and Otivio AS and is a
business mentor at the Royal Academy of Engineering’s accelerator
programme. He was named in the Sunday Times Maserati List as one of
the UK’s “Top 100 Game Changing Innovators and Entrepreneurs”.
Shaun Foy, Co-Founder and Chair of the Board of Directors,
ERS Genomics, commented: “On behalf of the Board and executive
team, I would like to welcome John as CEO. His experience uniquely
positions him to lead ERS Genomics through the next stage of its
development. I would also like to take the opportunity to thank
Eric Rhodes for his leadership over the past eight years. During
this time, ERS Genomics has been instrumental in providing access
to the foundational CRISPR/Cas9 patent portfolio, enabling research
and commercialisation across a broad range of applications within
the life sciences, industrial biology, agriculture, and veterinary
sciences sectors. We look forward to working with John as we
continue to make this Nobel Prize winning gene editing technology
widely available.”
John E Milad, CEO, ERS Genomics, said: “Gene editing
using CRISPR/Cas9 continues to gain momentum across a wide variety
of applications, playing a vital role in ushering in a golden age
for medical innovation and synthetic biology. ERS' mission is to
broaden the secure use of CRISPR/Cas9 by enhancing and expanding
accessibility, helping to drive the technology to its full
potential. I am delighted to join ERS, with their decade of
experience as a respected provider of CRISPR/Cas9 licensing, and
look forward to working with the team to continue making CRISPR
gene-editing available to the world.”
ERS Genomics provides licensing to CRISPR/Cas9 technology for
companies interested in pursuing its use in their commercial
programs. Comprising 100+ patents globally, ERS’ portfolio
encompasses CRISPR/Cas9 usage in all cells, including eukaryotic
and prokaryotic cells such as mammalian cells, bacteria, archaea,
yeasts, algae, and insects. ERS Genomics licenses these patents via
its direct license from Emmanuelle Charpentier and now has nearly
150 licenses in place worldwide.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240513334659/en/
Dr Ben Rutter Zyme Communications Tel: +44(0)7920 770 935 Email:
ben.rutter@zymecommunications.com